Mission Bio raises $70M to scale single-cell cancer R&D platform

Mission Bio's Tapestri (Mission Bio)

Mission Bio has raised $70 million to scale up a single-cell multi-omics technology with applications in the development of oncology drugs. The platform, which is in use at companies including Agios, enables researchers to simultaneously detect DNA and protein changes in single cells. 

Since spinning out of University of California, San Francisco in 2012, Mission Bio has established itself at the forefront of the single-cell analysis field. The sector has attracted considerable interest from institutional and strategic investors. 10x Genomics raised a $390 million IPO last year, adding to the sums it raised privately from investors including Venrock and Foresite Capital.

Now, Mission Bio has raised its largest round yet to support development of a single-cell platform, Tapestri, that is differentiated through its ability to simultaneously detect DNA and protein changes in single cells. The $70 million series C, which brings Mission Bio’s total fundraising to date to above $120 million, sets the company up to continue scaling the platform to support R&D.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

Tapestri has applications in cancer research, where its ability to detect DNA and protein changes in single cells could shed light on the drivers of tumor growth and resistance to medications. Mission Bio is also pitching the platform for use in the characterization of cell and gene therapies. Robert Ghenchev, head of Novo Growth, is among the people to buy into the potential of Tapestri.

“We are confident the technology will be used increasingly to unlock key insights into blood cancers, as well as solid tumor indications. We further see a clear opportunity in drug development, where the technology can bring great impact to patients’ lives,” Ghenchev said in a statement.

Ghenchev backed up his words with money. Novo Growth, part of Novo Holdings, led the series C with the support of another new investor, Soleus Capital, and existing backers Mayfield, Cota and Agilent.

The investor interest is mirrored by customer demand. Mission Bio lists Agios, LabCorp, Onconova Therapeutics, Stanford, MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center among the users of its technology.

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.